Seagen
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Seagen sits in the top decile of US sponsors by registered trial count (#270 of 15,742 sponsors by registered trial count).
Seagen: 84 sponsored US clinical trials, none currently recruiting.
Seagen sponsors 84 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 56 completed. 3 of these trials are in Phase 3-4 (later-stage) and 81 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, Large B-Cell, Diffuse, with 2 trials.
Top-decile sponsor footprint
Seagen ranks in the top decile of sponsors by registered trial count (#270 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
56 of 84 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (66.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
84 total, page 2 of 2
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
NCT01677390
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
NCT01461538
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
NCT01421667
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
NCT01309789
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
NCT01166490
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
NCT01100502
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
NCT01060904
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
NCT01026233
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
NCT01026415
A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
NCT01015911
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
NCT00947856
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
NCT00866047
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
NCT00848926
A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
NCT00650572
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
NCT00655837
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
NCT00502112
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
NCT00649584
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
NCT00528333
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
NCT00529503
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
NCT00525447
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
NCT00435916
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
NCT00430846
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT00283114
A Safety Study in Patients With Chronic Lymphocytic Leukemia
NCT00283101
A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
NCT00103779
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
NCT00099255
FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma
NCT00086333
Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma
NCT00079716
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
NCT00079755
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
NCT00031187
Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
NCT00028483
Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma
NCT00051571
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
NCT00051597
Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer
NCT00051584
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 50 |
| Phase 2 | 31 |
| Phase 3 | 3 |
Therapeutic Areas
How the Seagen early-phase archive is shaped
84 indexed studies, none listed as recruiting (0% open); 56 completed (67%).
Phase mix: 3 late (III/IV) vs 81 early (I/II) (early-phase heavy).
Top condition: Lymphoma, Large B-Cell, Diffuse (2 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Seagen: archived-pipeline peers nationwide
Peers matched on 84 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Seagen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 84 archived trials
- Intermountain Health Care · 85 trials · 13% recruiting
- Ipsen · 85 trials · 19% recruiting
- Ferring Pharmaceuticals · 83 trials · 5% recruiting
- National Jewish Health · 83 trials · 8% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Seagen page
84 registered trials is a research-attention snapshot, not an endorsement of Seagen or any single study.
- None of Seagen's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Lymphoma, Large B-Cell, Diffuse is the condition Seagen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, Large B-Cell, Diffuse trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Seagen pipeline card: 84 registered trials from official public datasets.Report a data error.